2022-RA-855-ESGO External validation of the ADNEX model to triage adnexal masses in Greece: A tertiary center study conducted by non-expert sonographers. (20th October 2022)
- Record Type:
- Journal Article
- Title:
- 2022-RA-855-ESGO External validation of the ADNEX model to triage adnexal masses in Greece: A tertiary center study conducted by non-expert sonographers. (20th October 2022)
- Main Title:
- 2022-RA-855-ESGO External validation of the ADNEX model to triage adnexal masses in Greece: A tertiary center study conducted by non-expert sonographers
- Authors:
- Anthoulakis, Christos
Bisxiniotis, Stavros
Zouzoulas, Dimitrios
Tsolakidis, Dimitrios
Chatzistamatiou, Kimon
Theodoulidis, Vasilis
Pitis, Sotiris
Ioannidou, Pinelopi
Pana, Antigoni
Theodoulidis, Iakovos
Pados, George
Grimbizis, Grigoris - Abstract:
- Abstract : Introduction/Background: To externally validate the Assessment of Different NEoplasias in the adneXa (ADNEX) model and evaluate its performance in differentiating benign from malignant adnexal masses. This study aimed to assess the diagnostic accuracy of the ADNEX model in a tertiary center in Greece. Methodology: A retrospective analysis of prospectively collected single-center university hospital data was performed from 2019 to 2022 by non-expert, although IOTA (International Ovarian Tumor Analysis Group) certified, sonographers. All patients were examined by transvaginal and transabdominal ultrasonography. Serum CA125 levels were measured and the diagnostic performance of the ADNEX model was assessed with CA125 as a predictor. Results: We retrieved data from 91 patients with 92 adnexal masses, of which 29 were excluded based on IOTA Simple Descriptors (SD) and Simple Rules (SR). Of the 62 patients with 62 adnexal masses included, 22/62 (35.5%) had benign and 40/62 (64.5%) had malignant tumors. Empirical area under the receiver operating characteristic curve (AUC) for the distinction between benign and malignant tumors was 0.75, sensitivity was 1.0, specificity was 0.5, precision was 0.784, negative predictive value was 1.0, false positive rate was 0.5, false negative rate was 0.0, and diagnostic accuracy was 0.823. Data follow a degenerate distribution and imply perfect decision performance. Conclusion: Our findings suggest that, when used by non-experts, IOTAAbstract : Introduction/Background: To externally validate the Assessment of Different NEoplasias in the adneXa (ADNEX) model and evaluate its performance in differentiating benign from malignant adnexal masses. This study aimed to assess the diagnostic accuracy of the ADNEX model in a tertiary center in Greece. Methodology: A retrospective analysis of prospectively collected single-center university hospital data was performed from 2019 to 2022 by non-expert, although IOTA (International Ovarian Tumor Analysis Group) certified, sonographers. All patients were examined by transvaginal and transabdominal ultrasonography. Serum CA125 levels were measured and the diagnostic performance of the ADNEX model was assessed with CA125 as a predictor. Results: We retrieved data from 91 patients with 92 adnexal masses, of which 29 were excluded based on IOTA Simple Descriptors (SD) and Simple Rules (SR). Of the 62 patients with 62 adnexal masses included, 22/62 (35.5%) had benign and 40/62 (64.5%) had malignant tumors. Empirical area under the receiver operating characteristic curve (AUC) for the distinction between benign and malignant tumors was 0.75, sensitivity was 1.0, specificity was 0.5, precision was 0.784, negative predictive value was 1.0, false positive rate was 0.5, false negative rate was 0.0, and diagnostic accuracy was 0.823. Data follow a degenerate distribution and imply perfect decision performance. Conclusion: Our findings suggest that, when used by non-experts, IOTA certified sonographers, the ADNEX model tends to overestimate the probability of malignant adnexal masses. The aforementioned accurately reflect the weaknesses of medical training and health care system in Greece. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 32(2022)Supplement 2
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 32(2022)Supplement 2
- Issue Display:
- Volume 32, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 32
- Issue:
- 2
- Issue Sort Value:
- 2022-0032-0002-0000
- Page Start:
- A74
- Page End:
- A74
- Publication Date:
- 2022-10-20
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2022-ESGO.163 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24562.xml